Market Place
Sourcing Support
FDA Confirms Para IV Patent for Cenobamate (Xcopri) Tablets
17 May 2024 //
FDA
XCOPRI® Approved For Alternate Oral, Nasogastric Tube Use
11 Apr 2024 //
PR NEWSWIRE
SK Life: XCOPRI® Data At AAN 2024
09 Apr 2024 //
PR NEWSWIRE
SK Life Science touts epilepsy support programs for Purple Day
25 Mar 2024 //
FIERCE PHARMA
Endo Announces Approval of XCOPRI (cenobamate tablets) in Canada
30 Jun 2023 //
PR NEWSWIRE
Endo Announces Approval of XCOPRI™ (cenobamate tablets) in Canada
29 Jun 2023 //
PR NEWSWIRE
Approval provided for Angelini’s cenobamate
16 May 2023 //
PHARMATIMES
Latest XCOPRI® (cenobamate tablets) CV Post-hoc Analysis Presented at the ANN
17 Apr 2023 //
PR NEWSWIRE
Cenobamate is Now Available in France and Belgium
07 Dec 2022 //
BUSINESSWIRE
SK life science Presents Latest Data on XCOPRI® (cenobamate tablets) CV
02 Dec 2022 //
PRNEWSWIRE
SK life science To Present Latest XCOPRI® (cenobamate tablets) CV Data
28 Nov 2022 //
PRNEWSWIRE
Health Canada accepts Paladin’s NDS for epilepsy-linked seizure therapy
09 Aug 2022 //
PHARMACEUTICAL-TECHNOLOGY
New Drug Filing for Cenobamate Accepted for Review in Canada and Israel
09 Aug 2022 //
PRNEWSWIRE
SK Biopharmaceuticals, Eurofarma Enter into Licensing Agreement for Cenobamate
14 Jul 2022 //
PRNEWSWIRE
Cenobamate for the Treatment of Drug-Resistant Focal-Onset Seizures in Adults
01 Apr 2022 //
BUSINESSWIRE
SK life science Presents Long-term Data on Adverse Events Associated with XCOPRI
31 Mar 2022 //
PRNEWSWIRE
SK life science to Present Latest XCOPRI CV Data at AAN 2022
24 Mar 2022 //
PRNEWSWIRE
NICE recommends cenobamate for treatment of adult epilepsy patients in UK
16 Nov 2021 //
PHARMATIMES
Epilepsia Publishes Two Post-hoc Analyses from Long-Term Study of XCOPRI®
12 Oct 2021 //
PRNEWSWIRE
Epilepsy drug receives MHRA marketing authorisation
18 Jun 2021 //
PHARMAFILE
ONTOZRY receives Marketing Authorisation in Great Britain
16 Jun 2021 //
FIRSTWORDPHARMA
SK Life’s dual TV ads for Xcopri target both docs and patients
13 May 2021 //
FIERCEPHARMA
EC approval for Ontozry
06 Apr 2021 //
PHARMATIMES
EC grants marketing authorisation to Angelini Pharma’s epilepsy treatment
31 Mar 2021 //
PHARMAFILE
ONTOZRY® (Cenobamate) Receives European Commission Approval
30 Mar 2021 //
PRNEWSWIRE
Cenobamate Receives Positive CHMP Opinion for Adjunctive Treatment
29 Jan 2021 //
PRNEWSWIRE
ONTOZRY™ (cenobamate) receives positive CHMP opinion for the adjunctive
29 Jan 2021 //
BIOSPACE
SK Life Science debuts Xcopri virtual experience for HCPs
15 Dec 2020 //
FIERCEPHARMA
Cenobamate Designated Promising Innovative Medicine (PIM) by the UK’s MHRA
11 Aug 2020 //
GLOBENEWSWIRE
SK Biopharmaceuticals emerges from pandemic delays with pitch for $822M IPO
16 Jun 2020 //
ENDPTS
SK Biopharmaceuticals Receives New Drug Development Awards
10 Jun 2020 //
BIOSPECTRUMASIA
Results of a Randomised Study Showing that Adjunctive Cenobamate
21 May 2020 //
GLOBENEWSWIRE
EC grants marketing authorisation to Angelini Pharma’s epilepsy treatment
05 Apr 2020 //
PHARMAFILE
EMA accepts Arvelle’s cenobamate MAA
27 Mar 2020 //
PHARMA TIMES
EMAAccepts Arvelle Therapeutics` Marketing Authorization Application
26 Mar 2020 //
PRNEWSWIRE
Epilepsy Therapy Xcopri Designated Schedule V Controlled Substance
12 Mar 2020 //
EMPR
FDA approves new treatment for adults with partial-onset seizures
22 Nov 2019 //
PR NEWSWIRE
FDA Approves XCOPRI® (cenobamate tablets)
21 Nov 2019 //
PR NEWSWIRE
Arvelle Acquires Exclusive Rights from SK Biopharmaceuticals` to Develop and Commercialize Cenobamate in EU
13 Feb 2019 //
BUSINESSWIRE
